Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: Comparison between complete cytogenetic responders treated in early and in late chronic phase

Haematologica

Volumn 92, Issue 11, 2007, Pages 1579-1580

  Palandri, Francesca ^a   Iacobucci, Ilaria ^a   Quarantelli, Fabrizio ^b   Castagnetti, Fausto ^a   Cilloni, Daniela ^c   Baccarani, Michele ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d St Orsola Malpighi University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PEGINTERFERON;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME;

CYTOGENETICS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PYRIMIDINES; TIME FACTORS;

EID: 36348964824     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12033     Document Type: Article

References (10)

1. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004;104:1979-88.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
3. Kaeda J, O'Shea D, Szydlo RM, Olavarria E, Dazzi F, Marin D, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006;107:4171-6.
4. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62-6.
5. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
6. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treatea chronic myeloid leukemia patients. Clin Cancer Res 2006; 12: 3037-42.
7. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, et al. Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103:2284-90.
8. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. GIMEMA Working Party on Chronic Myeloid Leukemia. Blood 2004; 104:4245-51.
9. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
10. Iacobucci I, Galletti L, Amabile M, Soverini S, Baccarani M, Martinelli G. Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. Haematologica 2007; 92:429-30.